Stock NOVO B NOVO NORDISK A/S
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Real-time Estimate Cboe Europe
Other stock markets
 03:00:30 2024-04-19 am EDT 		5-day change 1st Jan Change
865.4 DKK +0.32% Intraday chart for Novo Nordisk A/S -0.76% +23.58%
Apr. 18 India's Biocon developing its own version of Wegovy, clinical trial likely next year RE
Apr. 15 More than 250 websites selling fake weight-loss drugs reported by anti-counterfeit firm RE

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • According to Refinitiv, the company's ESG score for its industry is good.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 37.3 times its estimated earnings per share for the ongoing year.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • The company is highly valued given the cash flows generated by its activity.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
NOVO NORDISK A/S Stock Novo Nordisk A/S
+23.58% 550B
B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+27.97% 672B
C+
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.02% 351B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+14.85% 317B
B-
ABBVIE INC. Stock AbbVie Inc.
+6.25% 292B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+2.96% 211B
B+
NOVARTIS AG Stock Novartis AG
-0.41% 203B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-10.02% 194B
A+
PFIZER, INC. Stock Pfizer, Inc.
-11.81% 144B
C+
AMGEN INC. Stock Amgen Inc.
-8.80% 141B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. Ratings Novo Nordisk A/S